Product Description
Our lead compound, SXC-2023, is being developed to target psychiatric disorders in which glutamatergic dysfunction and oxidative stress play key roles.
Mechanisms of Action: CGA Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Promentis Pharmaceuticals, Inc.
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Cocaine-Related Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NIDA-SXC-Ph1b-001 | P1 |
Recruiting |
Cocaine-Related Disorders |
2024-12-01 |